CIK 0001453687 · Non-accelerated filer<br>Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-08 | SPRINGER TIMOTHY A Director | Purchase | +4,800 | $0.66 | $3K | 95,218 |
| 2024-02-07 | SPRINGER TIMOTHY A Director | Purchase | +2,400 | $0.66 | $2K | 90,418 |
| 2024-02-06 | SPRINGER TIMOTHY A Director | Purchase | +800 | $0.65 | $520 | 88,018 |
| 2024-01-17 | SPRINGER TIMOTHY A Director | Purchase | +800 | $0.69 | $552 | 87,218 |
| 2024-01-02 | Singer Michael Director | Grant or award | +178,000 | 288,123 | ||
| 2024-01-02 | Singer Michael Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | Davis Blaine Chief Financial Officer | Grant or award | +2,424,000 | 2,424,000 | ||
| 2024-01-02 | Davis Blaine Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +3,110,000 | 3,110,000 | ||
| 2024-01-02 | Jewell Christopher M Chief Scientific Officer | Grant or award | +778,200 | 778,200 | ||
| 2024-01-02 | Jewell Christopher M Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +998,000 | 998,000 | ||
| 2024-01-02 | Brunn Carsten President and CEO | Grant or award | +4,654,100 | 4,916,056 | ||
| 2024-01-02 | Brunn Carsten President and CEO | Grant or award · Employee Stock Option (right to buy) | +5,971,000 | 5,971,000 | ||
| 2024-01-02 | Sallin Aymeric Director | Grant or award | +178,000 | 178,000 | ||
| 2024-01-02 | Sallin Aymeric Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | BARABE TIMOTHY C Director | Grant or award | +178,000 | 428,013 | ||
| 2024-01-02 | BARABE TIMOTHY C Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | SPRINGER TIMOTHY A Director | Grant or award | +178,000 | 7,471,625 | ||
| 2024-01-02 | SPRINGER TIMOTHY A Director | Grant or award · Stock Option (Right to Buy) | +228,000 | 228,000 | ||
| 2024-01-02 | Miljkovic Milos Chief Medical Officer | Grant or award | +548,200 | 548,200 | ||
| 2024-01-02 | Miljkovic Milos Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +703,000 | 703,000 |
Page 13 of 16 · 316 trades